Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Jul 15;100(2):404–410. doi: 10.1172/JCI119547

A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications.

D C Chung 1, A P Smith 1, D N Louis 1, F Graeme-Cook 1, A L Warshaw 1, A Arnold 1
PMCID: PMC508204  PMID: 9218518

Abstract

The molecular pathogenesis of pancreatic endocrine tumors is largely unknown. Such tumors are more likely to develop in individuals with the von Hippel-Lindau (VHL) syndrome. We sought to determine whether allelic loss of the recently identified VHL tumor suppressor gene on chromosome 3p25-26 occurs in the more common sporadic forms of these tumors. Allelic loss on chromosome 3p was identified in 33% of 43 patients with endocrine tumors of the pancreas. The smallest common region of allelic loss, however, centered not at the VHL locus, but rather at 3p25, centromeric to VHL. Furthermore, no mutations of the VHL gene were identified in these tumors. Loss of alleles on chromosome 3p was associated with clinically malignant disease, whereas tumors with retained 3p alleles were more likely to be benign. Thus, the VHL gene does not appear to play a pathogenic role in the development of sporadic pancreatic endocrine tumors. Instead, a locus at chromosome 3p25 may harbor a novel pancreatic endocrine tumor suppressor gene, and allelic loss of this chromosomal region may serve as a molecular marker that helps distinguish benign from clinically malignant disease.

Full Text

The Full Text of this article is available as a PDF (196.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold A., Staunton C. E., Kim H. G., Gaz R. D., Kronenberg H. M. Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Engl J Med. 1988 Mar 17;318(11):658–662. doi: 10.1056/NEJM198803173181102. [DOI] [PubMed] [Google Scholar]
  2. Bordi C., Pilato F. P., D'Adda T. Comparative study of seven neuroendocrine markers in pancreatic endocrine tumours. Virchows Arch A Pathol Anat Histopathol. 1988;413(5):387–398. doi: 10.1007/BF00716987. [DOI] [PubMed] [Google Scholar]
  3. Caron H., van Sluis P., de Kraker J., Bökkerink J., Egeler M., Laureys G., Slater R., Westerveld A., Voûte P. A., Versteeg R. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996 Jan 25;334(4):225–230. doi: 10.1056/NEJM199601253340404. [DOI] [PubMed] [Google Scholar]
  4. Chen F., Kishida T., Yao M., Hustad T., Glavac D., Dean M., Gnarra J. R., Orcutt M. L., Duh F. M., Glenn G. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat. 1995;5(1):66–75. doi: 10.1002/humu.1380050109. [DOI] [PubMed] [Google Scholar]
  5. Collins F. S. Positional cloning moves from perditional to traditional. Nat Genet. 1995 Apr;9(4):347–350. doi: 10.1038/ng0495-347. [DOI] [PubMed] [Google Scholar]
  6. Crossey P. A., Foster K., Richards F. M., Phipps M. E., Latif F., Tory K., Jones M. H., Bentley E., Kumar R., Lerman M. I. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet. 1994 Jan;93(1):53–58. doi: 10.1007/BF00218913. [DOI] [PubMed] [Google Scholar]
  7. Crossey P. A., Maher E. R., Jones M. H., Richards F. M., Latif F., Phipps M. E., Lush M., Foster K., Tory K., Green J. S. Genetic linkage between von Hippel-Lindau disease and three microsatellite polymorphisms refines the localisation of the VHL locus. Hum Mol Genet. 1993 Mar;2(3):279–282. doi: 10.1093/hmg/2.3.279. [DOI] [PubMed] [Google Scholar]
  8. Crossey P. A., Richards F. M., Foster K., Green J. S., Prowse A., Latif F., Lerman M. I., Zbar B., Affara N. A., Ferguson-Smith M. A. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet. 1994 Aug;3(8):1303–1308. doi: 10.1093/hmg/3.8.1303. [DOI] [PubMed] [Google Scholar]
  9. Cryns V. L., Yi S. M., Tahara H., Gaz R. D., Arnold A. Frequent loss of chromosome arm 1p DNA in parathyroid adenomas. Genes Chromosomes Cancer. 1995 May;13(1):9–17. doi: 10.1002/gcc.2870130103. [DOI] [PubMed] [Google Scholar]
  10. Daly M. C., Xiang R. H., Buchhagen D., Hensel C. H., Garcia D. K., Killary A. M., Minna J. D., Naylor S. L. A homozygous deletion on chromosome 3 in a small cell lung cancer cell line correlates with a region of tumor suppressor activity. Oncogene. 1993 Jul;8(7):1721–1729. [PubMed] [Google Scholar]
  11. Duan D. R., Pause A., Burgess W. H., Aso T., Chen D. Y., Garrett K. P., Conaway R. C., Conaway J. W., Linehan W. M., Klausner R. D. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science. 1995 Sep 8;269(5229):1402–1406. doi: 10.1126/science.7660122. [DOI] [PubMed] [Google Scholar]
  12. Eubanks P. J., Sawicki M. P., Samara G. J., Gatti R., Nakamura Y., Tsao D., Johnson C., Hurwitz M., Wan Y. J., Passaro E., Jr Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumor formation. Am J Surg. 1994 Jan;167(1):180–185. doi: 10.1016/0002-9610(94)90071-x. [DOI] [PubMed] [Google Scholar]
  13. Evers B. M., Rady P. L., Sandoval K., Arany I., Tyring S. K., Sanchez R. L., Nealon W. H., Townsend C. M., Jr, Thompson J. C. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. Ann Surg. 1994 Jun;219(6):596–604. doi: 10.1097/00000658-199406000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fukui H., Fujimoto K., Mizuguchi H., Sakamoto K., Horio Y., Takai S., Yamada K., Ito S. Molecular cloning of the human histamine H1 receptor gene. Biochem Biophys Res Commun. 1994 Jun 15;201(2):894–901. doi: 10.1006/bbrc.1994.1786. [DOI] [PubMed] [Google Scholar]
  15. Ganly P. S., Rabbitts P. H. Polymerase chain reaction (PCR) for detection of HindIII polymorphism at the D3F15S2 locus. Nucleic Acids Res. 1991 Jul 11;19(13):3758–3758. [PMC free article] [PubMed] [Google Scholar]
  16. Gnarra J. R., Tory K., Weng Y., Schmidt L., Wei M. H., Li H., Latif F., Liu S., Chen F., Duh F. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994 May;7(1):85–90. doi: 10.1038/ng0594-85. [DOI] [PubMed] [Google Scholar]
  17. Graeme-Cook F., Nardi G., Compton C. C. Immunocytochemical staining for human chorionic gonadotropin subunits does not predict malignancy in insulinomas. Am J Clin Pathol. 1990 Feb;93(2):273–276. doi: 10.1093/ajcp/93.2.273. [DOI] [PubMed] [Google Scholar]
  18. Heitz P. U., Kasper M., Klöppel G., Polak J. M., Vaitukaitis J. L. Glycoprotein-hormone alpha-chain production by pancreatic endocrine tumors: a specific marker for malignancy. Immunocytochemical analysis of tumors of 155 patients. Cancer. 1983 Jan 15;51(2):277–282. doi: 10.1002/1097-0142(19830115)51:2<277::aid-cncr2820510219>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  19. Herman J. G., Latif F., Weng Y., Lerman M. I., Zbar B., Liu S., Samid D., Duan D. S., Gnarra J. R., Linehan W. M. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700–9704. doi: 10.1073/pnas.91.21.9700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Isobe M., Kumura Y., Murata Y., Takaki S., Tominaga A., Takatsu K., Ogita Z. Localization of the gene encoding the alpha subunit of human interleukin-5 receptor (IL5RA) to chromosome region 3p24-3p26. Genomics. 1992 Nov;14(3):755–758. doi: 10.1016/s0888-7543(05)80180-6. [DOI] [PubMed] [Google Scholar]
  21. Jen J., Kim H., Piantadosi S., Liu Z. F., Levitt R. C., Sistonen P., Kinzler K. W., Vogelstein B., Hamilton S. R. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994 Jul 28;331(4):213–221. doi: 10.1056/NEJM199407283310401. [DOI] [PubMed] [Google Scholar]
  22. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  23. Kanno H., Kondo K., Ito S., Yamamoto I., Fujii S., Torigoe S., Sakai N., Hosaka M., Shuin T., Yao M. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res. 1994 Sep 15;54(18):4845–4847. [PubMed] [Google Scholar]
  24. Killary A. M., Wolf M. E., Giambernardi T. A., Naylor S. L. Definition of a tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10877–10881. doi: 10.1073/pnas.89.22.10877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kok K., Osinga J., Carritt B., Davis M. B., van der Hout A. H., van der Veen A. Y., Landsvater R. M., de Leij L. F., Berendsen H. H., Postmus P. E. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature. 1987 Dec 10;330(6148):578–581. doi: 10.1038/330578a0. [DOI] [PubMed] [Google Scholar]
  26. Latif F., Tory K., Gnarra J., Yao M., Duh F. M., Orcutt M. L., Stackhouse T., Kuzmin I., Modi W., Geil L. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993 May 28;260(5112):1317–1320. doi: 10.1126/science.8493574. [DOI] [PubMed] [Google Scholar]
  27. Legerski R. J., Liu P., Li L., Peterson C. A., Zhao Y., Leach R. J., Naylor S. L., Siciliano M. J. Assignment of xeroderma pigmentosum group C (XPC) gene to chromosome 3p25. Genomics. 1994 May 1;21(1):266–269. doi: 10.1006/geno.1994.1256. [DOI] [PubMed] [Google Scholar]
  28. Levine A. J., Wu M. C., Chang A., Silver A., Attiyeh E. F., Lin J., Epstein C. B. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Ann N Y Acad Sci. 1995 Sep 30;768:111–128. doi: 10.1111/j.1749-6632.1995.tb12115.x. [DOI] [PubMed] [Google Scholar]
  29. Linehan W. M., Lerman M. I., Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA. 1995 Feb 15;273(7):564–570. [PubMed] [Google Scholar]
  30. Michelini S., Urbanek M., Dean M., Goldman D. Polymorphism and genetic mapping of the human oxytocin receptor gene on chromosome 3. Am J Med Genet. 1995 Jun 19;60(3):183–187. doi: 10.1002/ajmg.1320600303. [DOI] [PubMed] [Google Scholar]
  31. Naylor S. L., Carritt B., Boileau C., Beroud C., Alexander C., Allderdice P., Alimov A., Ashworth T., Bonifas J., Bugert P. Report of the sixth international workshop on human chromosome 3 mapping 1995. Cytogenet Cell Genet. 1996;72(4):255–270. doi: 10.1159/000134204. [DOI] [PubMed] [Google Scholar]
  32. Naylor S. L., Johnson B. E., Minna J. D., Sakaguchi A. Y. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature. 1987 Oct 1;329(6138):451–454. doi: 10.1038/329451a0. [DOI] [PubMed] [Google Scholar]
  33. Naylor S. L., Moore S., Garcia D., Xiang X., Xin X., Mohrer M., Reus B., Linn R., Stanton V., O'Connell P. Mapping 638 STSs to regions of human chromosome 3. Cytogenet Cell Genet. 1996;72(1):90–94. doi: 10.1159/000134170. [DOI] [PubMed] [Google Scholar]
  34. Pavelić K., Hrasćan R., Kapitanović S., Karapandza N., Vranes Z., Belicza M., Kruslin B., Cabrijan T. Multiple genetic alterations in malignant metastatic insulinomas. J Pathol. 1995 Dec;177(4):395–400. doi: 10.1002/path.1711770410. [DOI] [PubMed] [Google Scholar]
  35. Powell S. M., Zilz N., Beazer-Barclay Y., Bryan T. M., Hamilton S. R., Thibodeau S. N., Vogelstein B., Kinzler K. W. APC mutations occur early during colorectal tumorigenesis. Nature. 1992 Sep 17;359(6392):235–237. doi: 10.1038/359235a0. [DOI] [PubMed] [Google Scholar]
  36. Rowley H., Jones A., Spandidos D., Field J. Definition of a tumor suppressor gene locus on the short arm of chromosome 3 in squamous cell carcinoma of the head and neck by means of microsatellite markers. Arch Otolaryngol Head Neck Surg. 1996 May;122(5):497–501. doi: 10.1001/archotol.1996.01890170031007. [DOI] [PubMed] [Google Scholar]
  37. Roz L., Wu C. L., Porter S., Scully C., Speight P., Read A., Sloan P., Thakker N. Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. Cancer Res. 1996 Mar 15;56(6):1228–1231. [PubMed] [Google Scholar]
  38. Sekido Y., Bader S., Latif F., Gnarra J. R., Gazdar A. F., Linehan W. M., Zbar B., Lerman M. I., Minna J. D. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene. 1994 Jun;9(6):1599–1604. [PubMed] [Google Scholar]
  39. Shimizu T., Toguchida J., Kato M. V., Kaneko A., Ishizaki K., Sasaki M. S. Detection of mutations of the RB1 gene in retinoblastoma patients by using exon-by-exon PCR-SSCP analysis. Am J Hum Genet. 1994 May;54(5):793–800. [PMC free article] [PubMed] [Google Scholar]
  40. Tavtigian S. V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996 Mar;12(3):333–337. doi: 10.1038/ng0396-333. [DOI] [PubMed] [Google Scholar]
  41. Waber P. G., Lee N. K., Nisen P. D. Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the Von-Hippel Lindau tumor suppressor gene in head and neck cancer. Oncogene. 1996 Jan 18;12(2):365–369. [PubMed] [Google Scholar]
  42. Whaley J. M., Naglich J., Gelbert L., Hsia Y. E., Lamiell J. M., Green J. S., Collins D., Neumann H. P., Laidlaw J., Li F. P. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet. 1994 Dec;55(6):1092–1102. [PMC free article] [PubMed] [Google Scholar]
  43. Yashiro T., Fulton N., Hara H., Yasuda K., Montag A., Yashiro N., Straus F., 2nd, Ito K., Aiyoshi Y., Kaplan E. L. Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery. 1993 Oct;114(4):758–764. [PubMed] [Google Scholar]
  44. Yoshimoto K., Iwahana H., Fukuda A., Sano T., Saito S., Itakura M. Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res. 1992 Sep 15;52(18):5061–5064. [PubMed] [Google Scholar]
  45. Zeiger M. A., Zbar B., Keiser H., Linehan W. M., Gnarra J. R. Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von Hippel-Lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes Cancer. 1995 Jul;13(3):151–156. doi: 10.1002/gcc.2870130303. [DOI] [PubMed] [Google Scholar]
  46. van den Berg A., Hulsbeek M. F., de Jong D., Kok K., Veldhuis P. M., Roche J., Buys C. H. Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis. Genes Chromosomes Cancer. 1996 Jan;15(1):64–72. doi: 10.1002/(SICI)1098-2264(199601)15:1<64::AID-GCC9>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES